ISOS

Summary

Chronic diseases, demanding lengthy treatments, often push patients into inconvenience and discomfort. Repetitive intrusions of therapies for conditions like age-related macular degeneration, inflammatory bowel diseases or cancer not only disrupt lives but also risk side effects. The EIC-funded ISOS project aims to revolutionise healthcare with a pioneering biomedical solution. By seamlessly integrating genetically engineered bacteria into a biomaterial-based bioreactor, ISOS presents a visionary approach to in situ, on-demand fabrication and auto-renewed delivery of therapeutic compounds based on dynamic variation of pathological signals. In silico simulations allow modelling interactions between bacteria, biomolecules, cells, and tissues/organs, and define optimal microbiota ecosystems to treat the pathology with the best efficacy. The ISOS initiative holds the promise of transforming prolonged treatments into personalised, efficient, and minimally invasive healthcare experiences.

Northumbria investigators 

Prof Meng Zhang and Dr Paul James

Partners

SILK BIOMED, S.L. ES 

UNIVERSIDAD COMPLUTENSE DE MADRID ES 

UNIVERSITAET LEIPZIG DE 

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANG DE 

Alien tt Italy SRL Italy 

Funder

European Union, Horizon Europe, EIC Pathfinder Open; Grant Agreement ID: 101130454

Duration

3 years (1 December 2023- 30 November 2026)